# Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

> **NCT06951399** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rabin Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- NSCLC Stage IV Without EGFR/ALK Mutation
- NSCLC Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT06951399
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951399, "Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06951399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*